Quick Answer
BeOne Medicines Ltd. reported Diluted EPS of $0.19 per share for fiscal year 2025.
BeOne Medicines Ltd. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | $0.19 | +140.4% |
| 2024 | -$0.47 | +27.7% |
| 2023 | -$0.65 | +56.4% |
| 2022 | -$1.49 | -23.1% |
| 2021 | -$1.21 | +19.3% |
| 2020 | -$1.50 | -23.0% |
| 2019 | -$1.22 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $0.08 | +188.9% | +33.3% |
| June 30, 2025 | $0.06 | +166.7% | — |
| March 31, 2025 | $0.00 | +100.0% | +100.0% |
| September 30, 2024 | -$0.09 | -160.0% | +0.0% |
| June 30, 2024 | -$0.09 | +67.9% | +52.6% |
| March 31, 2024 | -$0.19 | +26.9% | -226.7% |
| September 30, 2023 | $0.15 | +136.6% | +153.6% |
| June 30, 2023 | -$0.28 | +33.3% | -7.7% |
- BeOne Medicines Ltd. showed an increase of +140.4% in Diluted EPS compared to the prior fiscal year.
- Over the 2019–2025 period, BeOne Medicines Ltd.’s diluted eps has grown by 115.6% (from $1.22 per share (loss) to $0.19 per share).
- The most recent figure is from BeOne Medicines Ltd.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: